yadC Antibody

What is YadC and why is it significant for plague vaccine development?

YadC is a novel outer membrane protein found in Yersinia pestis, the causative agent of plague. It has emerged as a promising vaccine candidate due to its ability to provide protection against F1-negative Y. pestis strains. The significance of YadC lies in its potential to overcome limitations of current plague vaccine approaches that primarily target the F1 capsular antigen.

Research has demonstrated that purified YadC fusion proteins (particularly GST-YadC137-409) can elicit protective immune responses in mouse models. When Swiss-Webster mice were immunized subcutaneously with GST-YadC137-409 and subsequently challenged intravenously with F1(-) Δpgm Y. pestis, they exhibited partial protection compared to control groups, indicating YadC's potential as a vaccine component .

How do YadC-induced immune responses differ from LcrV-induced responses?

The immune response triggered by YadC immunization appears to involve different mechanisms compared to LcrV, a well-studied plague vaccine antigen. YadC immunization correlates with a mixed IgG1/IgG3 antibody response, suggesting a balanced Th1/Th2 response. In contrast, LcrV immunization predominantly elicits an IgG1 response, indicating a Th2-biased immune profile .

When peripheral macrophages are stimulated with YadC, they produce predominantly pro-inflammatory cytokines, further supporting the involvement of Th1-type responses. This mixed Th1/Th2 response may contribute to YadC's protective efficacy against pneumonic plague, where in one study, 87% of GST-YadC137-409-immunized C57BL/6 mice survived intranasal challenge with F1(-) Y. pestis, compared to 50% survival in LcrV-immunized mice .

What methodological approaches are recommended for detecting YadC antibodies in serum samples?

For detecting YadC-specific antibodies in serum samples, enzyme-linked immunosorbent assay (ELISA) remains the gold standard method. When establishing an ELISA protocol:

• Coat high-binding microplate wells with purified recombinant YadC protein (typically 1-5 μg/mL in carbonate buffer, pH 9.6)

• Block with 3-5% BSA or similar blocking agent

• Apply serially diluted serum samples

• Detect bound antibodies using isotype-specific secondary antibodies (anti-IgG, anti-IgG1, anti-IgG2a, anti-IgG3)

• Develop with appropriate substrate and measure optical density

For more sensitive detection in research contexts, surface plasmon resonance (SPR) or biolayer interferometry can provide real-time antibody binding kinetics data, offering insights into affinity and specificity parameters that are crucial for understanding protective antibody responses.

What are the recommended experimental designs for evaluating cross-protection potential of YadC antibodies?

When designing experiments to evaluate the cross-protection potential of YadC antibodies against different Y. pestis strains, researchers should implement the following methodological approach:

• Multi-strain challenge models: Test protection against diverse Y. pestis strains, including:

  • F1-positive clinical isolates

  • F1-negative laboratory-derived strains

  • Strains with different virulence profiles (±pgm)

• Route-of-exposure comparison: Evaluate protection across multiple challenge routes:

• Passive transfer studies: Isolate YadC-specific antibodies from immunized animals and transfer to naïve recipients prior to challenge to confirm antibody-mediated protection mechanisms.

• Combination antigen approaches: Evaluate YadC antibodies alongside antibodies targeting other Y. pestis antigens (particularly LcrV) to assess potential synergistic protection .

How can researchers optimize YadC antibody binding affinity through rational design?

Optimizing YadC antibody binding affinity through rational design requires systematic application of structural and computational approaches. Based on modern antibody engineering principles, researchers should consider:

What approaches can help resolve contradictory data regarding YadC antibody protection mechanisms?

When faced with contradictory data regarding YadC antibody protection mechanisms, researchers should implement a multi-faceted approach to resolve discrepancies:

• Standardized reagent preparation: Ensure consistent preparation of YadC immunogens across experiments:

  • Define specific protein fragments (e.g., YadC137-409)

  • Standardize expression systems and purification protocols

  • Verify structural integrity via circular dichroism or thermal shift assays

• Comprehensive immune response profiling:

  • Analyze antibody isotype distribution (IgG1, IgG2a, IgG3)

  • Measure cytokine production from YadC-stimulated immune cells

  • Assess T cell responses using ELISPOT or flow cytometry

  • Evaluate neutrophil and macrophage activation patterns

• In vivo mechanistic studies:

  • Conduct adoptive transfer experiments with purified B cells, T cells, or serum

  • Use knockout mice lacking specific immune components

  • Employ in vivo imaging to track bacterial dissemination and immune cell recruitment

  • Compare results across different mouse strains (e.g., Swiss-Webster vs. C57BL/6)

• Direct antibody function assays:

  • Opsonophagocytosis assays to measure antibody-mediated uptake of Y. pestis

  • Bacterial agglutination tests

  • Complement activation assays

  • Direct neutralization of YadC function (if applicable)

How should researchers interpret differences in YadC antibody efficacy between mouse models?

Interpreting differences in YadC antibody efficacy between mouse models requires careful consideration of multiple variables that influence experimental outcomes. The methodological approach should include:

• Genetic background assessment: Different mouse strains exhibit varying immune responses to YadC immunization. For example, research has shown that C57BL/6 mice immunized with GST-YadC137-409 demonstrated 87% survival against pneumonic plague, while results may differ in other strains like Swiss-Webster mice . Consider:

  • Th1/Th2 balance inherent to each strain

  • Genetic polymorphisms affecting antibody repertoire

  • Natural resistance alleles to Y. pestis infection

• Standardized immunization parameters:

  Parameter	Recommendation	Rationale
  Antigen dose	20-50 μg YadC protein	Sufficient for robust response without excess
  Adjuvant	Alhydrogel (consistent concentration)	Enables comparison with previous studies
  Schedule	Prime + 2 boosts, 3-week intervals	Allows maturation of antibody response
  Route	Subcutaneous	Consistent tissue drainage and processing

• Comprehensive readout metrics: Rather than focusing solely on survival, measure:

  • Antibody titers by ELISA (multiple isotypes)

  • Antibody function (opsonization, neutralization)

  • Bacterial burden in key tissues

  • Inflammatory markers and cytokine levels

  • Histopathological assessment of infected tissues

• Statistical power considerations: Design experiments with sufficient animal numbers to detect biologically meaningful differences in protection (typically n=10-15 per group), with appropriate statistical analysis methods.

What are the current approaches for analyzing YadC epitope-antibody interactions?

Modern analysis of YadC epitope-antibody interactions requires sophisticated structural and biochemical approaches:

• Hydrogen-deuterium exchange mass spectrometry (HDX-MS): This technique can identify regions of YadC that are protected from solvent exchange upon antibody binding, revealing conformational epitopes not easily detected by other methods.

• Epitope mapping via mutational scanning: Generate a library of YadC variants with alanine substitutions at surface-exposed residues, then test antibody binding to identify critical interaction sites. This approach can be enhanced using deep mutational scanning coupled with next-generation sequencing.

• X-ray crystallography and cryo-electron microscopy: These structural approaches provide atomic-level details of antibody-YadC complexes, revealing precise binding modes and contact residues. Such information is invaluable for understanding protection mechanisms and guiding rational optimization.

• Computational epitope prediction: Employ algorithms that integrate sequence conservation, structural features, and physicochemical properties to predict potential epitopes on YadC. Tools like the OptCDR computational approach can then be used to design antibodies specifically targeting these epitopes .

• Surface plasmon resonance epitope binning: This approach allows researchers to classify multiple antibodies based on whether they compete for the same or overlapping epitopes, facilitating the development of antibody panels targeting distinct regions of YadC.

How can researchers leverage antibody databases for YadC antibody development?

The Antibody Society's Antibody Therapeutics Database (YAbS) provides valuable resources for researchers developing YadC antibodies. This database catalogs detailed information on over 2,900 commercially sponsored investigational antibody candidates and all approved antibody therapeutics, offering insights into molecular formats, targeted antigens, development status, and clinical timelines .

To leverage such databases effectively for YadC antibody research:

• Use standardized nomenclature when documenting YadC antibody characteristics

• Search for antibodies targeting similar bacterial outer membrane proteins to identify successful design principles

• Analyze antibody formats that have proven effective against other plague antigens

• Track development timelines and success rates of antibacterial antibodies

The database supports in-depth industry trends analysis, facilitating the identification of innovative developments that could be applied to YadC antibody research .

What methodological considerations are important when transitioning YadC antibodies from research to preclinical evaluation?

When transitioning YadC antibodies from basic research to preclinical evaluation, researchers should implement methodological approaches that address the following key considerations:

• Antibody production and characterization:

  • Establish stable cell lines producing consistent YadC antibodies

  • Perform extensive characterization (specificity, affinity, glycosylation)

  • Evaluate stability under various storage conditions

  • Generate reference standards for quality control

• Safety assessment:

  • Evaluate cross-reactivity with human tissues

  • Test for complement activation or cytokine release

  • Assess immunogenicity risk using in silico and in vitro methods

  • Determine half-life and pharmacokinetic properties in relevant animal models

• Efficacy testing in advanced models:

  • Progress from mice to larger animal models that better approximate human disease

  • Evaluate different dosing regimens and routes of administration

  • Test efficacy against diverse clinical Y. pestis isolates

  • Compare with existing plague countermeasures

• Regulatory considerations:

  • Design studies that align with FDA Animal Rule requirements (for biodefense applications)

  • Document manufacturing processes thoroughly

  • Prepare for pre-IND consultations with regulatory authorities